Expanded Medicare Coverage of Antiobesity Drugs May Cost Billions Each Year

Expanding Medicare coverage of a glucagon-like peptide-1 (GLP-1) receptor agonist to treat obesity could increase annual spending by several billion dollars, a study in Health Affairs found.